AR008531A1 - Análogos a heptapeptidos antagonistas de la oxitocina - Google Patents

Análogos a heptapeptidos antagonistas de la oxitocina

Info

Publication number
AR008531A1
AR008531A1 ARP970105543A ARP970105543A AR008531A1 AR 008531 A1 AR008531 A1 AR 008531A1 AR P970105543 A ARP970105543 A AR P970105543A AR P970105543 A ARP970105543 A AR P970105543A AR 008531 A1 AR008531 A1 AR 008531A1
Authority
AR
Argentina
Prior art keywords
heptapeptides
nucleus
oxytocine
antagonist
analogs
Prior art date
Application number
ARP970105543A
Other languages
English (en)
Inventor
Per Melin
Anders Nilsson
Carl-Johan Aurell
Jerzy Trojnar
Pierre Reviere
Robert Haigh
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of AR008531A1 publication Critical patent/AR008531A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los heptapéptidos análogos o sales farmacéuticamente aceptables de los mismos consisten en un nucleo hexapeptídico con un nitrogeno terminal S y unbeta-aminoalcohol con un carbono terminal Z unido al nucleo S por medio de una union amida, en el queel beta-aminoalcohol Z es -NR-CH(Q)-CH2-OH, donde Qrepresenta -(CH2)n-NH-A, donde n es 1-6 y A representa un H o -C(=NH)NH2, y R representa CH3 o C2H5, y el nucleo S es como se ve en la formula (1), donde X representa un D-alfa-aminoácido aromáticoe Y representa un alfa-aminoácido alifático, y posee una actividad antagonista a la oxitocina. También serevela: un método para su síntesis; composiciones farmacéuticas conteniendo estos análogos; la síntesis de dichas composiciones; un método decontrol decontracciones uterinas.
ARP970105543A 1996-11-26 1997-11-26 Análogos a heptapeptidos antagonistas de la oxitocina AR008531A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue

Publications (1)

Publication Number Publication Date
AR008531A1 true AR008531A1 (es) 2000-01-19

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105543A AR008531A1 (es) 1996-11-26 1997-11-26 Análogos a heptapeptidos antagonistas de la oxitocina

Country Status (35)

Country Link
US (1) US6143722A (es)
EP (1) EP0938496B1 (es)
JP (1) JP3405460B2 (es)
KR (1) KR100463132B1 (es)
CN (1) CN1129606C (es)
AR (1) AR008531A1 (es)
AT (1) ATE242264T1 (es)
AU (1) AU713424B2 (es)
BR (1) BR9713366B1 (es)
CA (1) CA2272990C (es)
CZ (1) CZ299532B6 (es)
DE (1) DE69722651T2 (es)
DK (1) DK0938496T3 (es)
EE (1) EE03832B1 (es)
ES (1) ES2203823T3 (es)
HK (1) HK1022481A1 (es)
HR (1) HRP970630B1 (es)
HU (1) HU228568B1 (es)
IL (1) IL129519A (es)
LT (1) LT4650B (es)
LV (1) LV12350B (es)
MY (1) MY125555A (es)
NO (1) NO321380B1 (es)
NZ (1) NZ336445A (es)
PL (1) PL189292B1 (es)
PT (1) PT938496E (es)
RO (1) RO120772B1 (es)
RU (1) RU2180668C2 (es)
SE (1) SE9604341D0 (es)
SI (1) SI20026B (es)
SK (1) SK283800B6 (es)
TR (1) TR199901028T2 (es)
UA (1) UA54459C2 (es)
WO (1) WO1998023636A1 (es)
ZA (1) ZA9710518B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
EP1480998B1 (en) * 2002-02-27 2006-11-22 Ferring BV Intermediates and methods for making heptapeptide oxytocin analogues
AU2003229735A1 (en) * 2002-05-02 2003-11-17 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
DK1530967T3 (da) * 2003-11-13 2006-07-03 Ferring Bv Blisterpakning og dertil hörende fast dosisform
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
AU2008283929B2 (en) 2007-08-06 2013-10-10 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
AU2009233429B2 (en) * 2008-03-31 2014-02-13 Ferring B.V. Oxytocin analogues
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
EP2712622B1 (en) 2008-05-21 2016-07-13 Ferring B.V. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
SG187038A1 (en) 2010-07-15 2013-02-28 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
WO2012121057A1 (ja) 2011-03-09 2012-09-13 Jitsubo株式会社 新規な非ペプチド性架橋構造を含む架橋ペプチド、ならびに該架橋ペプチドの合成方法および該方法に用いる新規な有機化合物
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
EP3501533A1 (en) 2014-12-22 2019-06-26 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN108290929A (zh) 2015-10-06 2018-07-17 辉凌公司 制造巴芦西班及其中间体的新型方法
AU2017205670B2 (en) 2016-01-04 2021-05-20 Merck Serono S.A. L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
CA3031252A1 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE9500249L (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
BR9713366B1 (pt) 2010-05-18
RU2180668C2 (ru) 2002-03-20
TR199901028T2 (xx) 1999-07-21
US6143722A (en) 2000-11-07
CZ299532B6 (cs) 2008-08-27
HRP970630A2 (en) 1998-10-31
ZA9710518B (en) 1998-06-10
JP3405460B2 (ja) 2003-05-12
HK1022481A1 (en) 2000-08-11
CN1238781A (zh) 1999-12-15
NO992532L (no) 1999-05-26
SK70499A3 (en) 2000-10-09
EE9900210A (et) 1999-12-15
WO1998023636A1 (en) 1998-06-04
NZ336445A (en) 2000-06-23
LT99052A (en) 2000-01-25
LV12350A (lv) 1999-09-20
NO321380B1 (no) 2006-05-02
KR100463132B1 (ko) 2004-12-23
PL189292B1 (pl) 2005-07-29
ES2203823T3 (es) 2004-04-16
EP0938496A1 (en) 1999-09-01
AU5142998A (en) 1998-06-22
DK0938496T3 (da) 2003-10-06
LT4650B (lt) 2000-04-25
SI20026B (sl) 2000-06-30
HUP0000577A3 (en) 2001-02-28
CA2272990A1 (en) 1998-06-04
BR9713366A (pt) 2000-01-25
LV12350B (en) 1999-11-20
HU228568B1 (en) 2013-04-29
NO992532D0 (no) 1999-05-26
HRP970630B1 (en) 2002-04-30
EE03832B1 (et) 2002-08-15
ATE242264T1 (de) 2003-06-15
IL129519A (en) 2004-09-27
RO120772B1 (ro) 2006-07-28
PT938496E (pt) 2003-10-31
HUP0000577A2 (hu) 2000-11-28
MY125555A (en) 2006-08-30
DE69722651T2 (de) 2004-04-08
JP2000507617A (ja) 2000-06-20
DE69722651D1 (en) 2003-07-10
AU713424B2 (en) 1999-12-02
EP0938496B1 (en) 2003-06-04
CN1129606C (zh) 2003-12-03
CA2272990C (en) 2002-11-19
KR20000069045A (ko) 2000-11-25
UA54459C2 (uk) 2003-03-17
IL129519A0 (en) 2000-02-29
SK283800B6 (sk) 2004-02-03
SI20026A (sl) 2000-02-29
SE9604341D0 (sv) 1996-11-26
CZ183299A3 (cs) 2000-05-17

Similar Documents

Publication Publication Date Title
AR008531A1 (es) Análogos a heptapeptidos antagonistas de la oxitocina
AU673398B2 (en) Compounds bearing sulphamoyl and amidino radicals, their preparation process and pharmaceutical compositions containing them
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
ES2159738T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
KR880003974A (ko) 디아민의 선택적 아미딘화 방법
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
ES2179318T3 (es) Derivados de acido cinamico y su uso como antagonistas de integrina.
PE20040781A1 (es) Compuestos de purina como ligandos del receptor cannabinoide
PE20020707A1 (es) Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c
PE52396A1 (es) Nuevo compuesto que puede mantener, aumentar o restaurar la sensibilidad de las celulas a los agentes terapeuticos o profilacticos
HUT68563A (en) Peptide analogs as irreversible interleukin-1-beta protease enzim inhibitors, pharmaceutical compositions containing the said peptidanalogs and process to prepare them
AU2005265164A2 (en) Non-natural amino acids
LV5794A4 (lv) Nonapeptidi ar bombezina antagonistu ipasibam
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
IT1244501B (it) Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
GB1176173A (en) Novel Fluorene Compounds
HRP20031055B1 (en) Novel immunomodulating compounds
HUP0401535A2 (hu) Szomatosztatin antagonisták és alkalmazásuk
ES515722A0 (es) Procedimientos para preparar derivados de tretalina.
ES2077878T3 (es) Derivados substituidos de amidas de aminoacidos, su obtencion y su empleo como fungicidas.
ES2031894T3 (es) Procedimiento para preparar derivados de 4(3h)-oxo-5,6,7,8-tetrahidropirido-(2,3-d)-pirimidina.
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
DeVita et al. Benzolactam growth hormone secretagogues: Carboxamides as replacements for the 2′-tetrazole moiety of L-692,429
SE8501988L (sv) Iminotiazolidinderivat
HUP0202698A2 (hu) Az N-metil-N-(3-{3-[2-tienilkarbonil]-pirazol-[1,5-alfa]-pirimidin-7-il}-fenil)acetamid polimorf módosulatai, előállításuk, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FG Grant, registration